Companies › MoonLake Immunotherapeutics
1 active drug program in 3 registered trials: 3 Phase 3; Immunology, Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| M-1095 Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Arthritis, Psoriatic | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06768671 | M-1095 | Phase 3 | Hidradenitis Suppurativa | Infectious disease | Sep 2026 |
| NCT06641089 | M-1095 | Phase 3 | Arthritis, Psoriatic | Immunology | Jan 2027 |
| NCT06641076 | M-1095 | Phase 3 | Arthritis, Psoriatic | Immunology | Feb 2027 |
Cash and short-term investments of $498m on 2026-09-30; operating cash outflow about $249m a year; runway about 24 months at that burn, to Sep 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Celltrion UCB Biopharma SRL Novartis Suzhou Suncadia Biopharmaceuticals Biocad Eli Lilly Zura Bio Sinocelltech Taizhou Mabtech Pharmaceutical
Zura Bio Chengdu Kangnuoxing Biopharma AnaptysBio Vor Biopharma Q32 Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.